- Home
- AEYE vs LXRX Comparison
AEYE vs LXRX Comparison
Compare AEYE & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEYE
- LXRX
- Stock Information
- Founded
- AEYE 2005
- LXRX 1995
- Country
- AEYE United States
- LXRX United States
- Employees
- AEYE N/A
- LXRX N/A
- Industry
- AEYE Computer Software: Prepackaged Software
- LXRX Biotechnology: Pharmaceutical Preparations
- Sector
- AEYE Technology
- LXRX Health Care
- Exchange
- AEYE Nasdaq
- LXRX Nasdaq
- Market Cap
- AEYE 138.0M
- LXRX 124.4M
- IPO Year
- AEYE N/A
- LXRX 2000
- Fundamental
- Price
- AEYE $12.46
- LXRX $0.70
- Analyst Decision
- AEYE Strong Buy
- LXRX Buy
- Analyst Count
- AEYE 5
- LXRX 4
- Target Price
- AEYE $26.40
- LXRX $3.67
- AVG Volume (30 Days)
- AEYE 117.6K
- LXRX 5.7M
- Earning Date
- AEYE 04-29-2025
- LXRX 05-13-2025
- Dividend Yield
- AEYE N/A
- LXRX N/A
- EPS Growth
- AEYE N/A
- LXRX N/A
- EPS
- AEYE N/A
- LXRX N/A
- Revenue
- AEYE $36,851,000.00
- LXRX $31,081,000.00
- Revenue This Year
- AEYE $20.29
- LXRX N/A
- Revenue Next Year
- AEYE $18.65
- LXRX $84.78
- P/E Ratio
- AEYE N/A
- LXRX N/A
- Revenue Growth
- AEYE 16.52
- LXRX 2481.48
- 52 Week Low
- AEYE $8.91
- LXRX $0.28
- 52 Week High
- AEYE $34.85
- LXRX $2.45
- Technical
- Relative Strength Index (RSI)
- AEYE 56.11
- LXRX 60.07
- Support Level
- AEYE $11.17
- LXRX $0.63
- Resistance Level
- AEYE $12.60
- LXRX $0.71
- Average True Range (ATR)
- AEYE 1.05
- LXRX 0.07
- MACD
- AEYE 0.12
- LXRX -0.00
- Stochastic Oscillator
- AEYE 91.08
- LXRX 55.00
About AEYE AudioEye Inc.
AudioEye Inc is a software solution provider delivering immediate ADA and WCAG accessibility compliance at scale. Through patented technology, subject matter expertise and proprietary processes, it is eradicating all barriers to digital accessibility, helping creators get accessible and supporting them with ongoing advisory and automated upkeep. Trusted by the ADP, Tommy Hilfiger, A360 Media, Samsung, Landry's and others. It helps everyone identify and resolve issues of accessibility and enhance user experiences, automating digital accessibility for the widest audiences.
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.